



Customer Number

24024

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on this 30th day of November, 2005.

Typed or Printed name of person signing this certificate:

Wendy A. Frick

Signed: Wendy A. Frick

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)	Examiner: Nolan, Patrick J.
Hazen, et al.	)	
	)	
Serial No.: 10/039,753	)	Art Unit: 1644
	)	
Filed: January 2, 2002	)	
	)	
For: <b>MYELOPEROXIDASE,</b>	)	Attorney Docket No.: 26473/04177
<b>A RISK INDICATOR FOR</b>	)	
<b>CARDIOVASCULAR DISEASE</b>	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT


Dear Sir:

The information enclosed and cited on the accompanying form PTO-1449 is hereby submitted in compliance with 37 CFR §§1.56, 1.97 and 1.98 for consideration by the Examiner in connection with the application.

Respectfully submitted,

Date: November 30, 2005

By: Pamela A. Docherty  
Pamela A. Docherty, Reg. No. 40,591  
(216) 622-8416

SEARCHED ~~SEARCHED~~ SERIALIZED PTO-1449APPLICANT'S INFORMATION  
DISCLOSURE STATEMENT

Atty. Docket No.: 26473/04177

Serial No.: 10/039,753

Applicant: Hazen, et al.

Filing Date: January 2, 2002

Group: 3736

## U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
	AA	5,731,208	March 24, 1998	Heinecke			Sep. 9, 1996
	AB	5,985,272	November 16, 1999	Deby, et al.			Dec. 31, 1996
	AC	6,096,556	August 1, 2000	Heinecke			Oct. 13, 1998
	AD	6,133,039	October 17, 2000	Heinecke			Jan. 18, 2000
	AE	6,953,666	October 11, 2005	Kinkade, Jr., et al.			Aug. 13, 2001
	AF	2003/0119792	June 26, 2003	Roca			Sep. 30, 2002

## FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
	AG	02/48715	June 20, 2002	WO			
	AH						
	AI						

## OTHER PRIOR ART

	AJ	"Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels" by Downs, et al., <u>JAMA</u> , May 27, 1998, Vol. 279, No. 20, pp. 1615-1622.
	AK	"The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels" by Sacks, et al., <u>The New England Journal of Medicine</u> , Vol. 335, No. 14, October 3, 1996, pp. 1001-1009.
	AL	"Beyond Cholesterol: Modifications of Low-Density Lipoprotein that Increase its Atherogenicity" by Steinberg, et al., <u>The New England Journal of Medicine</u> , Vol. 320, No. 14, April 6, 1989, pp. 915-924.
	AM	"Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors" by Takemoto, et al., <u>Arterioscler Thromb Vasc Biol</u> , 2001;21:1712-1719.
	AN	"The Evolving Role of Statins in the Management of Atherosclerosis" by Vaughan, et al., <u>Journal of the American College of Cardiology</u> , Vol 35, No. 1, 2000, pp. 1-10.
	AO	"Reduction of Plasma 24S-Hydroxycholesterol (Cerebrosterol) Levels Using High-Dosage Simvastatin in Patients with Hypercholesterolemia" by Locatelli, et al., <u>Arch Neurol</u> , Vol. 59, Feb. 2002, pp. 213-216.
	AP	"Alzheimer's Disease: Bad for the Heart, Bad for the Mind" by Marx, <u>Science</u> , Vol. 294, October 19, 2001, pp. 508-509.
	AQ	"3-Hydroxy-3-methylglutaryl-coenzyme A reductase in mRNA in Alzheimer and control brain" by Yasoima, et al., <u>Clinical Neuroscience and Neuropathology</u> , Vol. 12, No. 13, September 17, 2001, pp. 2935-2938.
	AR	"Lovastatin Treatment Decreases Mononuclear Cell Infiltration Into the CNS of Lewis Rats with Experimental Allergic Encephalomyelitis" by Stanislaus, et al., <u>Journal of Neuroscience Research</u> , 66:155-162 (2001).
	AS	"Effect of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors on the Progression of Calcific Aortic Stenosis" by Novaro, et al., <u>Circulation</u> , 2001; 104:2205-2209.

Examiner:

Date Considered:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.




Exhibit Form PTO-1449

APPLICANT'S INFORMATION  
DISCLOSURE STATEMENT

Atty. Docket No.: 26473/04177

Serial No.: 10/039,753

Applicant: Hazen, et al.

Filing Date: January 2, 2002

Group: 3736

## U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

## FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
	AG						
	AH						
	AI						

## OTHER PRIOR ART

	AJ	"Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events" by Ridker, et al., <u>The New England Journal of Medicine</u> , Vol. 344, No. 26, June 28, 2001, pp. 1959-1965.
	AK	"Rapid Reduction in C-Reactive Protein with Cerivastatin Among 785 Patients with Primary Hypercholesterolemia" by Ridker, <u>Circulation</u> , 2001; 103:1191-1193.
	AL	"Are Statins Anti-Inflammatory? Issues in the Design and Conduct of the Pravastatin Inflammation C-Reactive Protein Evaluation" by Ridker, et al., <u>Current Cardiology Reports</u> , 2000, 2:269-273.
	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	

Examiner:

Date Considered:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.